bs-1174R-Cy3 [Conjugated Primary Antibody]
CDKN2A/p19ARF Polyclonal Antibody, Cy3 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: CDKN2A/p19ARF

Immunogen Range: 65-169/169


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 12578

Swiss Prot: Q64364

Source: KLH conjugated synthetic peptide derived from mouse CDKN2A/p19ARF

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.

Conjugation: Cy3

Excitation/ Emission: 512,550nm/570,615nm

Size: 100ul

Concentration: 1ug/ul

Applications: IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 19


Cross Reactive Species: Rat

Predicted Cross Reactive Species: Mouse

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Liang, Wu, et al. "Knockdown BMI1 expression inhibits proliferation and invasion in human bladder cancer T24 cells." Molecular and cellular biochemistry (2013): 1-9.Read more>>
  • Xinchen Wang. et al. Enhancement of Bone-Forming Ability on Beta-Tricalcium Phosphate by Modulating Cellular Senescence Mechanisms Using Senolytics. Int J Mol Sci. 2021 Jan;22(22):12415Read more>>
  • Niuxin Yang. et al. Identification of Senescent Cells in Peri-Implantitis and Prevention of Mini-Implant Loss Using Senolytics. INT J MOL SCI. 2023 Jan;24(3):2507Read more>>
  • Wenqi Deng. et al. A Senomorphic-Conjugated Scaffold for Application of Senescent Cells in Regenerative Medicine. Advanced Therapeutics. 2023 Feb;:2200276Read more>>